Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three pharmaceutical agents—fentanyl, morphine, and propofol—used together for their synergistic effects in anesthesia and analgesia. Fentanyl and morphine are both potent opioid analgesics that act primarily as agonists at the mu-opioid receptor to provide pain relief. Propofol is a sedative-hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor, producing sedation, hypnosis, and amnesia. The combination may be used in clinical settings requiring deep sedation or general anesthesia with strong analgesia; however, this specific triple combination is not standard practice due to increased risk of respiratory depression and hemodynamic instability. Each component has distinct pharmacological actions but shares additive risks when combined.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + morphine + propofol.